Ameriprise Financial Inc Galectin Therapeutics Inc Transaction History
Ameriprise Financial Inc
- $356 Billion
- Q1 2025
Shares
2 transactions
Others Institutions Holding GALT
# of Institutions
102Shares Held
10.1MCall Options Held
587KPut Options Held
2.02M-
Vanguard Group Inc Valley Forge, PA2.19MShares$2.85 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.56MShares$2.03 Million0.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ1.22MShares$1.59 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA853KShares$1.11 Million0.0% of portfolio
-
Geneos Wealth Management Inc.427KShares$555,6650.01% of portfolio
About GALECTIN THERAPEUTICS INC
- Ticker GALT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,426,000
- Market Cap $77.3M
- Description
- Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...